{"id":"W3093653710","doi":"10.1158/1078-0432.ccr-20-2669","title":"Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors","year":2020,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Adverse effect; Internal medicine; Toxicity; Oncology; Renal cell carcinoma; Incidence (geometry); Melanoma; Clinical trial; Lung cancer; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07739396,0.002005528,0.007277972,0.001110417,0.0005206237,0.003067628,0.001505475,0.001845477,0.00836821],"category_scores_gemma":[0.06417426,0.0009416151,0.01698252,0.001566357,0.001047101,0.00274038,0.001406696,0.003250278,0.0008953669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001459733,"about_ca_system_score_gemma":0.001903228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002787362,"about_ca_topic_score_gemma":0.0007614288,"domain_scores_codex":[0.9237887,0.06216695,0.007205538,0.003223773,0.002793357,0.0008216201],"domain_scores_gemma":[0.9575695,0.02594194,0.008330201,0.004886073,0.002468436,0.0008038363],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.529833,0.001101531,0.01300339,0.08720675,0.2579467,0.0002616678,0.0003125142,0.003937427,0.004562687,0.003410358,0.005029708,0.09339426],"study_design_scores_gemma":[0.5047628,0.06868953,0.03241606,0.01269401,0.312906,0.0005751587,0.0001751517,0.0109214,0.003715879,0.01764674,0.03522621,0.0002710712],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3398823,0.431343,0.0982349,0.007034556,0.006482014,0.08574884,0.0100709,0.001675343,0.01952826],"genre_scores_gemma":[0.8542498,0.01940129,0.03836486,0.005004114,0.0009868328,0.07395682,0.003743218,0.0003602192,0.003932827],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9226061,"threshold_uncertainty_score":0.4093032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6305114855276522,"score_gpt":0.6382727501066128,"score_spread":0.007761264578960536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}